Spots Global Cancer Trial Database for her2
Every month we try and update this database with for her2 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Study to Evaluate the Effect of Metformin in the Prevention of HG in HR[+]/HER2[-] PIK3CA-mut Advanced BC Patients | NCT04300790 | Breast Cancer | Alpelisib Metformin Fulvestrant Letrozole Exemestane Vildagliptin Tamoxifen | 18 Years - | MedSIR | |
| A Study of MRG002 in the Treatment of Patients With HER2-positive Advanced Solid Tumors | NCT04941339 | Advanced Solid ... | MRG002 | 18 Years - 75 Years | Shanghai Miracogen Inc. | |
| A Study of MRG002 in the Treatment of Patients With HER2-low Locally Advanced or Metastatic Breast Cancer (BC) | NCT04742153 | Advanced or Met... | MRG002 | 18 Years - | Shanghai Miracogen Inc. | |
| DS-8201a in Human Epidermal Growth Factor Receptor2 (HER2)-Expressing Colorectal Cancer (DESTINY-CRC01) | NCT03384940 | Colorectal Neop... | DS-8201a | 18 Years - | Daiichi Sankyo | |
| A Phase II Study of RC48-ADC in Subjects With HER2 Positive Metastatic or Unresectable Urothelial Cancer | NCT03507166 | Urothelial Carc... Advanced Cancer | RC48-ADC | 18 Years - 80 Years | RemeGen Co., Ltd. | |
| Validation of the CPS+EG, Neo-Bioscore and Modified Neo-Bioscore Staging Systems After PST of BC in China | NCT03437837 | Breast Cancer Neoadjuvant The... Neoplasm Stagin... Estrogen Recept... Histological Gr... HER2 Prognosis Predictive Valu... | 18 Years - 75 Years | Peking University First Hospital | ||
| A Study of Trastuzumab Emtansine, Paclitaxel, and Pertuzumab in Patients With HER2-Positive, Locally Advanced or Metastatic Breast Cancer | NCT00951665 | Metastatic Brea... | paclitaxel pertuzumab [Per... trastuzumab emt... paclitaxel trastuzumab emt... | 18 Years - | Genentech, Inc. | |
| Assessing an Oral EGFR Inhibitor, Sunvozertinib in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR or HER2 Mutation (WU-KONG1) | NCT03974022 | Non-Small Cell ... | Sunvozertinib | 18 Years - | Dizal Pharmaceuticals | |
| A Study of MRG002 in the Treatment of HER2-positive Unresectable Locally Advanced or Metastatic Urothelium Cancer | NCT04839510 | Locally Advance... Metastatic Urot... | MRG002 | 18 Years - 75 Years | Shanghai Miracogen Inc. | |
| TRAstuzumab and Pertuzumab for HER2+ Resectable Oesophageal Cancer | NCT05188313 | Esophageal Canc... Esophageal Aden... | Trastuzumab Pertuzumab Paclitaxel Carboplatin | 18 Years - | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | |
| Exploratory Study of Breast Cancer With ABY025 | NCT01216033 | Breast Cancer | 111-In-ABY-025 | 20 Years - | Biomedical Radiation Sciences | |
| Trial With Eribulin or Eribulin+ Endocrine Therapy in Locally-recurrent or Metastatic Breast Cancer Patients | NCT03795012 | Breast Cancer | Eribulin | 18 Years - | MedSIR | |
| Assessing the Immunogenicity of pING-hHER3FL | NCT03832855 | Advanced Cancer | pING-hHER3FL | 18 Years - | Duke University | |
| Study to Assess dHER2+AS15 Cancer Vaccine Given in Combination With Lapatinib to Patients With Metastatic Breast Cancer | NCT00952692 | Metastatic Brea... | dHER2 + AS15 AS... Lapatinib | 18 Years - | Duke University | |
| A Study of MRG002 in the Treatment of Patients With HER2-mutated Unresectable/Metastatic Non-small Cell Lung Cancer (NSCLC). | NCT05141786 | Non-small- Cell... | MRG002 | 18 Years - 75 Years | Shanghai Miracogen Inc. | |
| Diarrhea Prevention and Prophylaxis With Crofelemer in HER2 Positive Breast Cancer Patients | NCT02910219 | Breast Cancer | Crofelemer | 18 Years - | Georgetown University | |
| Study of ACTR T Cell Product in Combination With Trastuzumab in Subjects With HER2-Positive Advanced Solid Tumor Cancers | NCT03680560 | Solid Tumor HER-2 Protein O... | ACTR T Cell Pro... Trastuzumab | 18 Years - 75 Years | Cogent Biosciences, Inc. | |
| Evaluation of 68-GaNOTA-Anti-HER2 VHH1 Uptake in Brain Metastasis of Cancer Patients | NCT03331601 | Carcinoma Receptor, ErbB-... | 68GaNOTA-Anti-H... | 18 Years - | Universitair Ziekenhuis Brussel | |
| Trial of ZD1839 (Iressa) and Tamoxifen in Breast Cancer Patients | NCT00206492 | Breast Cancer | Iressa Tamoxifen | 18 Years - | Baylor Breast Care Center | |
| Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing Cancers | NCT02892123 | HER2-expressing... | ZW25 (Zanidatam... Paclitaxel Capecitabine Vinorelbine Tucatinib Tucatinib | 18 Years - | Jazz Pharmaceuticals | |
| Disitamab Vedotin Combined With Fruquintinib for mCRC With HER2 Expression | NCT05661357 | HER2 Colorectal Canc... | Disitamab Vedot... | 18 Years - 75 Years | Zhongnan Hospital | |
| Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03) | NCT04379596 | Gastric Cancer | Fluorouracil (5... Capecitabine Durvalumab Oxaliplatin Trastuzumab Trastuzumab der... Cisplatin Pembrolizumab Volrustomig Rilvegostomig | 18 Years - 130 Years | AstraZeneca | |
| The Oncopanel Pilot (TOP) Study | NCT02171286 | Colorectal Canc... Advanced Non-Sm... Advanced Melano... Gastrointestina... Patients With D... | 18 Years - | British Columbia Cancer Agency | ||
| PRS-343 in HER2-Positive Solid Tumors | NCT03330561 | HER2-positive B... HER2-positive G... HER2-positive B... HER2-positive S... | PRS-343 | 18 Years - | Pieris Pharmaceuticals, Inc. | |
| Carvedilol for the Prevention of Anthracycline/Anti-HER2 Therapy Associated Cardiotoxicity Among Women With HER2-Positive Breast Cancer Using Myocardial Strain Imaging for Early Risk Stratification | NCT02177175 | Breast Cancer | Carvedilol placebo | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| A Phase I Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of CUDC-101 in Patients With Advanced Solid Tumors | NCT00728793 | Tumors | CUDC-101 | 18 Years - | Curis, Inc. | |
| Alpha Radiation Emitters Device for the Treatment of Newly Diagnosed Breast Carcinoma Patients With Distant Metastases | NCT03970967 | Breast Carcinom... Metastatic Brea... Invasive Breast... Distant Metasta... | Device: Radiati... | 45 Years - | Alpha Tau Medical LTD. | |
| A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer | NCT03929666 | HER2-expressing... | ZW25 (Zanidatam... Capecitabine Cisplatin Fluorouracil Leucovorin Oxaliplatin Bevacizumab Gemcitabine | 18 Years - | Jazz Pharmaceuticals | |
| SNX-5422 to Treat Solid Tumor Cancers and Lymphomas | NCT00644072 | Lymphoma Neoplasms | SNX-5422 | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Detection of Amplification of Her2 Fluorescent in Situ Hybridization (FISH) in Breast Tissue Sections | NCT01066507 | Breast Cancer | 21 Years - | Applied Spectral Imaging Ltd. | ||
| A Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma | NCT03653507 | Locally Advance... Locally Advance... Metastatic Gast... Metastatic Gast... | zolbetuximab oxaliplatin capecitabine placebo | 18 Years - | Astellas Pharma Inc | |
| A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer | NCT02202746 | Breast Cancer Metastatic Brea... MBC HER2 Positive HER2 Estrogen Recept... ER Triple Negative | Lucitanib | 18 Years - | Clovis Oncology, Inc. | |
| Explorative Phase II Study of Perioperative Treatment in Patients With Adenocarcinoma of the Gastroesophageal Junction or Stomach | NCT01472029 | Adenocarcinoma ... Adenocarcinoma ... | 5-FU, leucovori... Post-operative ... | 18 Years - | AIO-Studien-gGmbH | |
| Repeatability of 68-GaNOTA-Anti-HER2 VHH1 PET/CT in Breast Carcinoma Patients | NCT03924466 | Metastatic Brea... Locally Advance... Cancer of Pancr... Solid Tumor Wit... Salivary Gland ... Gastric Cancer Endometrial Can... Uterine Cancer Non Small Cell ... Biliary Tract C... Cholangiocarcin... Colorectal Canc... Urothelial Carc... Prostate Cancer | 68GaNOTA-Anti-H... | 18 Years - | Universitair Ziekenhuis Brussel | |
| Observation of Medical Treatments in MBC HER2-negative Patients | NCT02365831 | Metastatic Brea... | Observation of ... | 18 Years - | Consorzio Oncotech | |
| Repeatability of 68-GaNOTA-Anti-HER2 VHH1 PET/CT in Breast Carcinoma Patients | NCT03924466 | Metastatic Brea... Locally Advance... Cancer of Pancr... Solid Tumor Wit... Salivary Gland ... Gastric Cancer Endometrial Can... Uterine Cancer Non Small Cell ... Biliary Tract C... Cholangiocarcin... Colorectal Canc... Urothelial Carc... Prostate Cancer | 68GaNOTA-Anti-H... | 18 Years - | Universitair Ziekenhuis Brussel | |
| FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors | NCT03319459 | HER2 Positive G... Colorectal Canc... Head and Neck S... EGFR Positive S... Advanced Solid ... HER2-positive B... Hepatocellular ... Non Small Cell ... Renal Cell Carc... Pancreatic Canc... Melanoma | FATE-NK100 Cetuximab Trastuzumab | 18 Years - | Fate Therapeutics | |
| Preoperative Systemic Therapy vs Upfront Surgery in HER2 Positive Early Breast Cancer | NCT04249440 | Breast Cancer HER2 Preoperative Sy... | Preoperative sy... | 18 Years - 80 Years | Zhejiang Cancer Hospital | |
| HERPET- A Novel PET Imaging Study of HER2 in Breast Cancer | NCT03827317 | Breast Cancer | [18F]GE-226 | 18 Years - | Imperial College London | |
| Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers | NCT04464967 | Advanced Solid ... Metastatic Canc... HER2-positive B... HER2-positive G... HER-2 Protein O... Esophageal Canc... Ovarian Cancer Endometrium Can... Bladder Cancer Pancreatic Canc... Colorectal Canc... Non Small Cell ... EGF-R Positive ... Head and Neck S... Triple Negative... Cervical Cancer Sarcoma | SNK01 Trastuzumab Cetuximab | 18 Years - 75 Years | NKGen Biotech, Inc. | |
| A Study of MRG002 in the Treatment of HER2-positive Unresectable, Locally Advanced or Metastatic Biliary Tract Cancer | NCT04837508 | Advanced or Met... | MRG002 | 18 Years - 75 Years | Shanghai Miracogen Inc. | |
| Adjuvant Trastuzumab, Pertuzumab Plus Docetaxel in the Treatment of Early HER2-positive Breast Cancer | NCT02625441 | Breast Cancer | Pertuzumab Trastuzumab | 18 Years - | Helsinki University Central Hospital | |
| Study Comparing Lapatinib (GW572016) And Letrozole Versus Letrozole In Subjects With Advanced Or Metastatic Breast Cancer | NCT00073528 | Breast Neoplasm... | Lapatinib Letrozole Placebo | 18 Years - | Novartis | |
| Carvedilol for the Prevention of Anthracycline/Anti-HER2 Therapy Associated Cardiotoxicity Among Women With HER2-Positive Breast Cancer Using Myocardial Strain Imaging for Early Risk Stratification | NCT02177175 | Breast Cancer | Carvedilol placebo | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| A Phase II Study of Everolimus in Combination With Exemestane Versus Everolimus Alone Versus Capecitabine in Advance Breast Cancer. | NCT01783444 | Breast Cancer | Capecitabine Exemestane Everolimus | 18 Years - | Novartis | |
| HER2-directed Biosimilar in Breast Cancer: Real World ePRO | NCT05234021 | HER2-positive B... Biosimilar Patient Reporte... | 18 Years - | OnkoZentrum Zürich AG | ||
| Real-world Study of HER2-overexpressed Advanced Solid Tumors After Progression of First-line Standard Therapy | NCT05649163 | HER2 Advanced Gastri... Advanced Gastro... Advanced Solid ... | Disitamab Vedot... | 18 Years - | Peking University | |
| Deciphering Afatinib Response and Resistance With INtratumour Heterogeneity | NCT02183883 | Non-small Cell ... | Afatinib | 18 Years - | University College, London | |
| Trastuzumab-pkrb Combined With Modified FOLFOX-6 in Biliary Tract Cancer Patients Progressed on First Line Therapy | NCT04722133 | HER2 Positive A... | HERZUMA+mFOLFOX | 19 Years - | Yonsei University | |
| Treatment of HER2-Positive Metastatic Breast Cancer With Herceptin and Bevacizumab (Antibodies Against HER2 and VEGF) | NCT00095706 | Breast Cancer | Bevacizumab (dr... | 18 Years - 75 Years | Translational Oncology Research International | |
| DS-8201a in Patients With Cancer That Tests Positive for Human Epidermal Growth Factor Receptor 2 (HER2) Protein | NCT03368196 | Adenocarcinoma,... Neoplasm, Breas... | DS-8201a | 20 Years - | Daiichi Sankyo | |
| Radiation Omission in Patients With HER2 Overexpressing Tumors With Pathologic Complete Response | NCT05371860 | Breast Cancer HER2-positive B... | Omit breast rad... | 40 Years - | Cedars-Sinai Medical Center | |
| Clinical Study on the Efficacy and Safety of RC48-ADC in the Treatment of Metastatic Castration Resistant Prostate Cancer (mCRPC) | NCT05955209 | Metastatic Cast... | Disitamab Vedot... | 18 Years - | Peking University Cancer Hospital & Institute | |
| INST 0514C- Biologic Correlative Study: Trial of GW572016 in HER2 Overexpressing Breast Cancer Patients | NCT00455039 | Breast Cancer | GW572016 | - | University of New Mexico | |
| A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies for HER2-positive Cancers | NCT05091528 | HER2-positive B... HER2-positive G... HER2-positive C... HER2-expressing... | SBT6050 trastuzumab der... tucatinib trastuzumab capecitabine trastuzumab der... | 18 Years - | Silverback Therapeutics | |
| Phase 2 Study of Poziotinib in Participants With NSCLC Having EGFR or HER2 Exon 20 Insertion Mutation | NCT03318939 | NSCLC | Poziotinib | 18 Years - | Spectrum Pharmaceuticals, Inc | |
| Trial of ZD1839 (Iressa) and Tamoxifen in Breast Cancer Patients | NCT00206492 | Breast Cancer | Iressa Tamoxifen | 18 Years - | Baylor Breast Care Center | |
| Phase I Study to Assess the Safety, Tolerability, and Pharmacokinetics of Orally Administered CUDC-101 in Cancer Patients | NCT01702285 | Cancer | CUDC-101 | 18 Years - | Curis, Inc. | |
| PAM50 HER2-enriched Phenotype as a Predictor of Response to Dual HER2 Blockade in HER2-positive Early Breast Cancer | NCT01973660 | Breast Cancer | Lapatinib Trastuzumab Endocrine Thera... Paclitaxel | 18 Years - | SOLTI Breast Cancer Research Group | |
| PRS-343 in Combination With Atezolizumab in HER2-Positive Solid Tumors | NCT03650348 | HER2-positive B... HER2-positive G... HER2-positive B... HER2-positive S... | PRS-343 in Comb... | 18 Years - | Pieris Pharmaceuticals, Inc. | |
| A Study of MRG002 in the Treatment of Patients With HER2-positive Advanced Solid Tumors | NCT04941339 | Advanced Solid ... | MRG002 | 18 Years - 75 Years | Shanghai Miracogen Inc. | |
| KD019 and Trastuzumab in Patients With Esophagus, Gastroesophageal Junction and Stomach Cancer | NCT02205463 | Esophageal Canc... Stomach Cancer | KD019 | 18 Years - | NYU Langone Health | |
| RC48 Combined With Tislelizumab for Bladder Sparing Treatment in NMIBC With BCG Treatment Failure and HER2 Expression | NCT05957757 | Non-Muscle Inva... HER2 | RC48 Tislelizumab | 18 Years - | RenJi Hospital | |
| A Study to Learn About How Food and Esomeprazole Affect the Level of BAY2927088 in the Blood When Taken Together in Healthy Participants | NCT06378658 | Advanced Non-sm... EGFR Mutation HER2 Mutation Healthy Volunte... | BAY2927088 Esomeprazole Food | 18 Years - 55 Years | Bayer | |
| A Long-term Follow-up Study for Cardiac Safety in the Patients With HER2 (+) Breast Cancer Who Have Completed the SB3-G31-BC | NCT02771795 | Breast Neoplasm... | Herceptin (tras... SB3 (proposed t... | 18 Years - | Samsung Bioepis Co., Ltd. | |
| Tucatinib Plus Trastuzumab in Patients With HER2+ Colorectal Cancer | NCT03043313 | Metastatic Colo... | Trastuzumab Tucatinib | 18 Years - | Seagen Inc. | |
| Trastuzumab-pkrb Combined With Modified FOLFOX-6 in Biliary Tract Cancer Patients Progressed on First Line Therapy | NCT04722133 | HER2 Positive A... | HERZUMA+mFOLFOX | 19 Years - | Yonsei University | |
| Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations. | NCT02000622 | Breast Cancer M... BRCA 1 Gene Mut... BRCA 2 Gene Mut... | Olaparib Physician's cho... | 18 Years - 99 Years | AstraZeneca | |
| MRI Screening for Brain Metastases Among Patients With Triple Negative or HER2+ Stage II or III Breast Cancer | NCT06247449 | Breast Cancer | Brain imaging Analysis of cir... Testing Morbidi... | 18 Years - | Sunnybrook Health Sciences Centre | |
| A Phase II Study of Everolimus in Combination With Exemestane Versus Everolimus Alone Versus Capecitabine in Advance Breast Cancer. | NCT01783444 | Breast Cancer | Capecitabine Exemestane Everolimus | 18 Years - | Novartis | |
| Efficacy Study of Single Agent Trastuzumab or Lapatinib to Treat HER2-Overexpressing Breast Cancer | NCT00842998 | Metastatic Brea... | Trastuzumab or ... | 18 Years - 75 Years | Azienda Ospedaliera Ordine Mauriziano di Torino | |
| Carvedilol for the Prevention of Anthracycline/Anti-HER2 Therapy Associated Cardiotoxicity Among Women With HER2-Positive Breast Cancer Using Myocardial Strain Imaging for Early Risk Stratification | NCT02177175 | Breast Cancer | Carvedilol placebo | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| A Study of DB-1303 in Advanced/Metastatic Solid Tumors | NCT05150691 | HER2-positive A... | DB-1303 Pertuzumab Inje... Ritonavir Itraconazole | 18 Years - | DualityBio Inc. | |
| Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing Cancers | NCT02892123 | HER2-expressing... | ZW25 (Zanidatam... Paclitaxel Capecitabine Vinorelbine Tucatinib Tucatinib | 18 Years - | Jazz Pharmaceuticals | |
| The Oncopanel Pilot (TOP) Study | NCT02171286 | Colorectal Canc... Advanced Non-Sm... Advanced Melano... Gastrointestina... Patients With D... | 18 Years - | British Columbia Cancer Agency | ||
| DS-8201a in HER2-positive Gastric Cancer That Cannot Be Surgically Removed or Has Spread (DESTINY-Gastric02) | NCT04014075 | Adenocarcinoma ... Adenocarcinoma ... | Trastuzumab der... | 18 Years - | Daiichi Sankyo | |
| Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer | NCT00777101 | Advanced Breast... Breast Cancer | Neratinib Lapatinib Capecitabine | 18 Years - | Puma Biotechnology, Inc. | |
| Therapy With Bevacizumab (BEV), Epirubicin, and Cyclophosphamide Followed by Docetaxel Plus Trastuzumab and BEV Given as Neoadjuvant or Adjuvant Therapy for Women With Locally Advanced HER2 Positive Invasive Breast Cancer | NCT00464646 | Breast Cancer | Epirubicin Cyclophosphamid... Docetaxel Trastuzumab Bevacizumab | 18 Years - | NSABP Foundation Inc | |
| French National Observatory of the Patients With Non-small Cell Lung (NSCLC) and Molecular Testings | NCT01700582 | Carcinoma, Non-... ALK Gene Mutati... KRAS Gene Mutat... BRAF Gene Mutat... | 18 Years - | Intergroupe Francophone de Cancerologie Thoracique | ||
| NeoPHOEBE: Neoadjuvant Trastuzumab + BKM120 in Combination With Weekly Paclitaxel in HER2-positive Primary Breast Cancer | NCT01816594 | HER2-positive N... | BKM120 Trastuzumab Paclitaxel BKM120 Placebo | 18 Years - | Novartis |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
